HRP20140153T1 - Anti-sklerostin antitijela - Google Patents
Anti-sklerostin antitijela Download PDFInfo
- Publication number
- HRP20140153T1 HRP20140153T1 HRP20140153AT HRP20140153T HRP20140153T1 HR P20140153 T1 HRP20140153 T1 HR P20140153T1 HR P20140153A T HRP20140153A T HR P20140153AT HR P20140153 T HRP20140153 T HR P20140153T HR P20140153 T1 HRP20140153 T1 HR P20140153T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- bone loss
- disease
- use according
- bone
- Prior art date
Links
- 206010065687 Bone loss Diseases 0.000 claims 24
- 208000001132 Osteoporosis Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 210000003054 facial bone Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000000736 Amenorrhea Diseases 0.000 claims 1
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 201000000304 Cleidocranial dysplasia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000000088 Enchondromatosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000017670 Juvenile Paget disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 1
- 208000012583 Menkes disease Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000034789 Multiple hereditary exostosis Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000035175 Oligomenorrhea Diseases 0.000 claims 1
- 206010030295 Oligomenorrhoea Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000013612 Parathyroid disease Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 1
- 208000002607 Pseudarthrosis Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 102000019307 Sclerostin Human genes 0.000 claims 1
- 108050006698 Sclerostin Proteins 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047623 Vitamin C deficiency Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000008321 Winchester syndrome Diseases 0.000 claims 1
- 208000008919 achondroplasia Diseases 0.000 claims 1
- 208000022567 adolescent idiopathic scoliosis Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 231100000540 amenorrhea Toxicity 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000010103 fibrous dysplasia Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000009434 installation Methods 0.000 claims 1
- 208000024884 ischemic bone disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 201000000022 melorheostosis Diseases 0.000 claims 1
- 230000001617 migratory effect Effects 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000029985 osteonecrosis of the jaw Diseases 0.000 claims 1
- 206010031281 osteopoikilosis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 208000010233 scurvy Diseases 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000022148 skull disease Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
Claims (13)
1. Anti-sklerostin antitijelo za uporabu u postupku inhibicije resorpcije kosti kod čovjeka, naznačen time, da postupak obuhvaća davanje osobi anti-sklerostin antitijela u količini od 1 mg/kg do 5 mg/kg, pri čemu je antitijelo antisklerostin antitijelo ili fragment koje:
(a) pokazuje afinitet vezanja za sclerostin SEQ ID NO: 1 od manje ili jednako 1x10 - 7M, i
(b) sadrži CDR-H1 od SEQ ID NO: 245, CDR -H2 od SEQ ID NO: 246, CDR -H3 od SEQ ID NO: 247, CDR - L1 u SEQ ID NO: 78, CDR - L2 SEQ ID NO: 79 iCDR - L3 SEQ ID NO: 80, pri čemu je:
[image]
2. Antitijelo za uporabu prema zahtjevu 1, naznačeno time, da je količina Anti-sklerostin antitijela koja se primjenjuje od 1 mg/kg do 3 mg/kg.
3. Antitijelo za uporabu prema zahtjevu 1 ili 2, naznačeno time, da je količina Anti-sklerostin antitijela koja se primjenjuje oko 2 mg/kg.
4. Antitijelo za uporabu prema zahtjevu 1 ili 2, naznačeno time, da je količina Anti-sklerostin primjenjenog antitijela oko 3 mg/kg.
5. Antitijelo za uporabu prema zahtjevu 1, naznačeno time, da postupak uključuje davanje doze od 70 do 450 mg.
6. Antitijelo za uporabu prema zahtjevu 1, naznačeno time, da postupak uključuje davanje doze od oko 140 mg.
7. Antitijelo za uporabu prema zahtjevu 1, naznačeno time, da postupak uključuje davanje doze od oko 210 mg.
8. Antitijelo za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time, da se količina anti-sklerostin antitijela se daje subjektu jednom svaka dva tjedna.
9. Antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačeno time, da se anti-sklerostin antitijelo daje subjektu jednom mjesečno.
10. Antitijelo za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da je antitijelo humano antitijelo, humanizirano antitijelo, monoklonalno antitijelo ili himerno antitijelo.
11. Antitijelo za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da osoba pati od poremećaja povezanih s kostima odabranih iz skupine koju čine: ahondroplazija, cleidocranial dysostosis, enchondromatosis, fibrozna displazija, Gaucher-ova bolest, hipofosfatemični rahitis, Marfan-ov sindrom, multipla nasljedna egzostoza, neurofibromatoza, osteogenesis imperfecta, osteoporoza, Osteopoikilosis, sklerotične lezije, pseudoartroza, piogeni osteomijelitis, periodontalna bolest, gubitak kosti induciran anti-epileptički lijekovima, primarni i sekundarni hiperparatiroidizam, sindrom obiteljskog hiperparatiroidizam, gubitak kosti induciran bestežinskim stanjem, osteoporoza u muškaraca, gubitak koštane mase u postmenopauzi, osteoartritis, bubrega osteodistrofija, infiltrativni poremećaji kosti, oralni gubitak kosti, osteonekroza čeljusti, juvenilna Pagetova bolest, Melorheostosis, metaboličke bolesti kostiju, mastocitoza, anemija/bolest srpastih stanica, gubitak kosti povezan s presađivanjem organa, gubitak kosti u transplantacije bubrega, sistemski eritemski lupus, ankilozni spondilitis, epilepsija, juvenilni artritis, talasemija, mucopolysaccharidoses, Fabrijeva bolest, Turnerov sindrom, Downov sindrom, Klinefelterov sindrom, lepra, Perthesova bolest, idiopatska skolioza adolescenata, multisistemska bolest upalna bolest novorođenčeta, Winchester sindrom, Menkesova bolest, Wilsonova bolest, ishemijske bolesti kostiju, Legg - Calve - Perthesova bolest, regionalna migracijska osteoporoza, anemije stanja, stanja uzrokovana steroidima, gubitak koštane mase izazvana glukokortikoidima, gubitak koštane mase izazvana heparinom, poremećaj koštane srži, skorbut, pothranjenost, nedostatak kalcija, osteoporoza, osteopenija, alkoholizam, kronična bolest jetre, post- menopauze, kronična upalna stanja, reumatoidni artritis, upalne bolesti crijeva, ulcerozni kolitis, upalni kolitis, Crohnova bolest, oligomenoreja, amenoreja, trudnoća, dijabetes melitus, hipertireoza, poremećaji štitnjače, poremećaji nusštitnjače, Cushing-ova bolest, akromegalija, hipogonadizam, imobilizacija ili neaktivnost, refleksna simpatička distrofija, regionalna osteoporoza, gubitak kosti povezan sa instalacijom umjetnog zgloba, gubitak koštane mase povezan s HIV-om, gubitak kosti povezan sa nedostatkom hormona rasta, gubitak koštane mase povezan s cističnom fibrozom, gubitak koštane mase povezan s kemoterapijom, gubitak kosti induciranog tumora, gubitak koštane mase povezan s rakom, gubitak kosti povezan sa uklanjanjem organa koji izlučuju hormone, multipli mijelom, gubitak kosti induciran lijekovima, anoreksije nervoze, bolesti povezane s gubitkom kosti lica, bolesti povezane s gubitkom kranijalnih kosti, bolesti povezane s gubitkom čeljustnih kosti, gubitak koštane mase povezan s bolestima lubanje, gubitak koštane mase povezan sa starenjem, gubitak kosti lica povezan sa starenjem, gubitak kranijalnih kosti povezan sa starenjem, gubitak kosti čeljusti povezan sa starenjem, gubitak kosti povezan sa starenjem lubanje i gubitak kosti povezan sa svemirskim putovanjima.
12. Antitijelo za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time, da je osoba žena u post-menopauzi.
13. Antitijelo za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time, da osoba pati od osteoporoze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97302407P | 2007-09-17 | 2007-09-17 | |
| PCT/US2008/076679 WO2009039175A2 (en) | 2007-09-17 | 2008-09-17 | Method for inhibiting bone resorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140153T1 true HRP20140153T1 (hr) | 2014-04-25 |
Family
ID=40371592
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240493TT HRP20240493T3 (hr) | 2007-09-17 | 2008-09-17 | Postupak za inhibiranje resorpcije kostiju |
| HRP20140153AT HRP20140153T1 (hr) | 2007-09-17 | 2014-02-18 | Anti-sklerostin antitijela |
| HRP20160872TT HRP20160872T1 (hr) | 2007-09-17 | 2016-07-14 | Postupak za inhibiciju resorpcije kosti |
| HRP20201438TT HRP20201438T1 (hr) | 2007-09-17 | 2020-09-09 | Metoda inhibiranja resorpcije kosti |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240493TT HRP20240493T3 (hr) | 2007-09-17 | 2008-09-17 | Postupak za inhibiranje resorpcije kostiju |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160872TT HRP20160872T1 (hr) | 2007-09-17 | 2016-07-14 | Postupak za inhibiciju resorpcije kosti |
| HRP20201438TT HRP20201438T1 (hr) | 2007-09-17 | 2020-09-09 | Metoda inhibiranja resorpcije kosti |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US8017120B2 (hr) |
| EP (5) | EP4335510A3 (hr) |
| JP (2) | JP5643094B2 (hr) |
| AR (2) | AR068471A1 (hr) |
| AU (1) | AU2008302313C1 (hr) |
| CA (2) | CA2699905C (hr) |
| CL (1) | CL2008002775A1 (hr) |
| CY (3) | CY1114961T1 (hr) |
| DK (4) | DK3085386T3 (hr) |
| ES (4) | ES2975587T3 (hr) |
| FI (1) | FI3725329T3 (hr) |
| HK (1) | HK1182017A1 (hr) |
| HR (4) | HRP20240493T3 (hr) |
| HU (3) | HUE030168T2 (hr) |
| LT (3) | LT2556841T (hr) |
| MX (1) | MX2010002971A (hr) |
| PL (4) | PL3725329T3 (hr) |
| PT (4) | PT3085386T (hr) |
| SI (4) | SI3085386T1 (hr) |
| TW (2) | TWI612972B (hr) |
| WO (1) | WO2009039175A2 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP2423226A3 (en) * | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| ES2930183T3 (es) | 2006-12-29 | 2022-12-07 | Ossifi Mab Llc | Métodos para alterar el crecimiento óseo mediante la administración del antagonista o agonista de Sost o Wise |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| US20090142766A1 (en) * | 2007-11-09 | 2009-06-04 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
| MX2010006519A (es) * | 2007-12-14 | 2010-10-15 | Amgen Inc | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. |
| TW202423982A (zh) | 2008-04-11 | 2024-06-16 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| PL3195880T3 (pl) | 2010-05-14 | 2020-06-01 | Amgen Inc. | Wysoce stężone preparaty przeciwciała przeciwko sklerostynie |
| TR201909531T4 (tr) | 2010-11-05 | 2019-07-22 | Novartis Ag | Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇ |
| KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| RU2013130002A (ru) * | 2010-12-02 | 2015-01-10 | Дзе Вашингтон Юниверсити | Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками |
| US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
| MY170720A (en) | 2011-03-25 | 2019-08-27 | Amgen Inc | Antibody formulations |
| US20140127192A1 (en) * | 2011-04-19 | 2014-05-08 | Amgen Inc | Method for treating osteoporosis |
| JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
| PT2739311T (pt) * | 2011-08-04 | 2018-03-26 | Amgen Inc | Método para tratamento de defeitos de lacunas ósseas |
| EA201490676A1 (ru) * | 2011-09-22 | 2015-02-27 | Экселиксис, Инк. | Способ лечения остеопороза |
| EP2797953B1 (en) | 2011-12-28 | 2020-06-03 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| EP2869844B2 (en) | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| CA2962969C (en) | 2014-09-30 | 2023-03-21 | Washington University | Tau kinetic measurements |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| NZ754676A (en) | 2016-12-21 | 2023-06-30 | Mereo Biopharma 3 Ltd | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE |
| CA3093457A1 (en) * | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| CN111658821A (zh) * | 2020-06-03 | 2020-09-15 | 深圳市百吉因生物科技有限公司 | 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用 |
| WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| HUT54407A (en) | 1987-12-15 | 1991-02-28 | Commw Scient Ind Res Org | Process for producing ribozimes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| JPH06502311A (ja) | 1990-10-22 | 1994-03-17 | フォックス・チェイス・キャンサー・センター | Ｒｎａ療法を提供するためのｄｎａ構造 |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| TW205553B (hr) | 1991-04-25 | 1993-05-11 | Chugai Pharmaceutical Co Ltd | |
| US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| US5864027A (en) | 1993-06-07 | 1999-01-26 | Genentech, Inc. | HIV envelope polypeptides |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| WO1995030003A2 (en) | 1994-04-29 | 1995-11-09 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| JP4124486B2 (ja) | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| US6117911A (en) | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
| CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| EP1000152A2 (en) | 1997-08-01 | 2000-05-17 | Genset | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| GB9818881D0 (en) * | 1998-08-28 | 1998-10-21 | Glaxo Group Ltd | Compounds |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| CA2361553A1 (en) | 1999-01-29 | 2000-08-03 | Zhenping Zhu | Antibodies specific to kdr and uses thereof |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| CA2371434A1 (en) | 1999-06-09 | 2000-12-14 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
| US6197592B1 (en) * | 1999-07-15 | 2001-03-06 | Bio-Rad Laboratories, Inc. | Clinical control materials for detection of bone resorptive markers |
| WO2001064885A1 (en) | 2000-03-02 | 2001-09-07 | Amgen, Inc. | Chordin-like-2 molecules and uses thereof |
| WO2001092308A2 (en) | 2000-06-01 | 2001-12-06 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| CA2412110A1 (en) | 2000-06-19 | 2001-12-27 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| EP1341814A2 (en) | 2000-09-01 | 2003-09-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| AU2002357107B2 (en) | 2001-12-06 | 2008-01-10 | Biocontrol Systems, Inc. | Sample collection and testing system |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| EP2277522B1 (en) | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Methods for increasing or decreasing bone density and identifying molecules |
| AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| JP4976653B2 (ja) | 2002-11-01 | 2012-07-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス | 免疫刺激性ＣｐＧオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法 |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| JP4660471B2 (ja) | 2003-03-14 | 2011-03-30 | セルテック アール アンド ディー， インコーポレイテッド | ＴＧＦβ結合タンパク質のリガンドおよびその使用 |
| WO2004090105A2 (en) | 2003-04-02 | 2004-10-21 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| DE602005017362D1 (de) | 2004-02-06 | 2009-12-10 | Dharmacon Inc | Stabilisierte rnas als transfektionskontrollen und silencing-reagentien |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
| EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| WO2007080129A1 (en) | 2006-01-13 | 2007-07-19 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
| EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| US20080120672A1 (en) | 2006-11-21 | 2008-05-22 | Francesco Caggioni | Methods and Apparatus for Weighted Multicasting of Data Streams |
| ES2930183T3 (es) | 2006-12-29 | 2022-12-07 | Ossifi Mab Llc | Métodos para alterar el crecimiento óseo mediante la administración del antagonista o agonista de Sost o Wise |
| CA2675639A1 (en) | 2007-02-02 | 2008-08-07 | Novartis Ag | Modulators of sclerostatin biniding partners for treating bone-related disorders |
| EA018204B1 (ru) * | 2007-03-20 | 2013-06-28 | Эли Лилли Энд Компани | Антитела против склеростина |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| US20100254980A1 (en) | 2007-11-02 | 2010-10-07 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
| MX2010006519A (es) | 2007-12-14 | 2010-10-15 | Amgen Inc | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. |
| PE20100092A1 (es) | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| CA2815181C (en) | 2010-10-27 | 2020-09-15 | William Gleason Richards | Dkk1 antibodies and methods of use |
-
2008
- 2008-09-16 CL CL2008002775A patent/CL2008002775A1/es unknown
- 2008-09-17 AR ARP080104044A patent/AR068471A1/es not_active Application Discontinuation
- 2008-09-17 TW TW104134720A patent/TWI612972B/zh active
- 2008-09-17 CA CA2699905A patent/CA2699905C/en active Active
- 2008-09-17 LT LTEP12180292.0T patent/LT2556841T/lt unknown
- 2008-09-17 PL PL20174310.1T patent/PL3725329T3/pl unknown
- 2008-09-17 SI SI200832137T patent/SI3085386T1/sl unknown
- 2008-09-17 WO PCT/US2008/076679 patent/WO2009039175A2/en active Application Filing
- 2008-09-17 SI SI200832217T patent/SI3725329T1/sl unknown
- 2008-09-17 AU AU2008302313A patent/AU2008302313C1/en active Active
- 2008-09-17 DK DK16162068.7T patent/DK3085386T3/da active
- 2008-09-17 DK DK20174310.1T patent/DK3725329T3/da active
- 2008-09-17 SI SI200831170T patent/SI2195026T1/sl unknown
- 2008-09-17 SI SI200831663A patent/SI2556841T1/sl unknown
- 2008-09-17 PT PT161620687T patent/PT3085386T/pt unknown
- 2008-09-17 LT LTEP16162068.7T patent/LT3085386T/lt unknown
- 2008-09-17 FI FIEP20174310.1T patent/FI3725329T3/fi active
- 2008-09-17 HU HUE12180292A patent/HUE030168T2/en unknown
- 2008-09-17 EP EP23219258.3A patent/EP4335510A3/en active Pending
- 2008-09-17 PT PT88326905T patent/PT2195026E/pt unknown
- 2008-09-17 EP EP12180292.0A patent/EP2556841B9/en not_active Revoked
- 2008-09-17 DK DK08832690.5T patent/DK2195026T3/da active
- 2008-09-17 ES ES20174310T patent/ES2975587T3/es active Active
- 2008-09-17 LT LTEP20174310.1T patent/LT3725329T/lt unknown
- 2008-09-17 ES ES16162068T patent/ES2815677T3/es active Active
- 2008-09-17 PL PL12180292.0T patent/PL2556841T3/pl unknown
- 2008-09-17 PL PL08832690T patent/PL2195026T3/pl unknown
- 2008-09-17 HU HUE16162068A patent/HUE050653T2/hu unknown
- 2008-09-17 HR HRP20240493TT patent/HRP20240493T3/hr unknown
- 2008-09-17 PT PT121802920T patent/PT2556841T/pt unknown
- 2008-09-17 EP EP16162068.7A patent/EP3085386B1/en not_active Revoked
- 2008-09-17 ES ES12180292.0T patent/ES2581754T3/es active Active
- 2008-09-17 EP EP20174310.1A patent/EP3725329B1/en active Active
- 2008-09-17 EP EP08832690.5A patent/EP2195026B1/en active Active
- 2008-09-17 DK DK12180292.0T patent/DK2556841T3/en active
- 2008-09-17 MX MX2010002971A patent/MX2010002971A/es active IP Right Grant
- 2008-09-17 TW TW097135666A patent/TWI526222B/zh active
- 2008-09-17 US US12/212,327 patent/US8017120B2/en active Active
- 2008-09-17 PL PL16162068T patent/PL3085386T3/pl unknown
- 2008-09-17 CA CA3170836A patent/CA3170836A1/en active Pending
- 2008-09-17 HU HUE20174310A patent/HUE066466T2/hu unknown
- 2008-09-17 JP JP2010525108A patent/JP5643094B2/ja active Active
- 2008-09-17 PT PT201743101T patent/PT3725329T/pt unknown
- 2008-09-17 ES ES08832690.5T patent/ES2445792T3/es active Active
-
2011
- 2011-04-19 US US13/090,058 patent/US8329176B2/en active Active
- 2011-04-19 US US13/090,075 patent/US8440193B2/en active Active
-
2013
- 2013-04-11 US US13/860,954 patent/US9089553B2/en active Active
- 2013-08-12 HK HK13109416.2A patent/HK1182017A1/zh unknown
-
2014
- 2014-02-18 HR HRP20140153AT patent/HRP20140153T1/hr unknown
- 2014-03-07 CY CY20141100183T patent/CY1114961T1/el unknown
- 2014-09-03 JP JP2014178609A patent/JP5764704B2/ja active Active
-
2015
- 2015-06-16 US US14/740,838 patent/US10273293B2/en active Active
-
2016
- 2016-07-14 HR HRP20160872TT patent/HRP20160872T1/hr unknown
- 2016-07-15 CY CY20161100685T patent/CY1117908T1/el unknown
-
2017
- 2017-10-27 AR ARP170103001A patent/AR109995A2/es unknown
-
2018
- 2018-11-14 US US16/191,068 patent/US11091537B2/en active Active
-
2020
- 2020-09-02 CY CY20201100823T patent/CY1123463T1/el unknown
- 2020-09-09 HR HRP20201438TT patent/HRP20201438T1/hr unknown
-
2021
- 2021-07-15 US US17/376,304 patent/US20210340236A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140153T1 (hr) | Anti-sklerostin antitijela | |
| JP2010539190A5 (hr) | ||
| HRP20130803T1 (hr) | Sredstva za vezanje sklerostina | |
| HRP20170679T1 (hr) | Epitopi sklerostina | |
| JP7242449B2 (ja) | ヘテロ二量体免疫グロブリン | |
| JP2008539726A5 (hr) | ||
| US20240269274A1 (en) | Treatment for bone diseases | |
| RU2017134592A (ru) | Антитела к muc16 и их применение | |
| JP2018183173A5 (hr) | ||
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| RU2014143770A (ru) | Новое антитело против siglec-15 | |
| HRP20201266T1 (hr) | Anti fg23 antitijelo i farmaceutski pripravak koji sadrži isto | |
| US20100015665A1 (en) | Antibodies and diagnostics | |
| JP2005508176A5 (hr) | ||
| JP2015524256A5 (hr) | ||
| RU2017119185A (ru) | Антитела против fgfr2/3 и способы их применения | |
| SI2514436T1 (en) | IL-22 for use in the treatment of microbial diseases | |
| JP2008525034A5 (hr) | ||
| WO2008061013A2 (en) | Antibody-based diagnostics and therapeutics | |
| JP2020506208A5 (hr) | ||
| JP2017502695A5 (hr) | ||
| RU2014143798A (ru) | Антитело к сиглек-15 с модифицированной cdr | |
| EP2739311B1 (en) | Method for treating bone gap defects | |
| JP2019513015A5 (hr) | ||
| US11851483B2 (en) | Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen |